Form 4: United Therapeutics Director Christopher Patusky Executes Stock Option and Sells Shares Under 10b5-1 Plan
SEC Form 4
Director Christopher Patusky exercised stock options and sold shares of United Therapeutics Corp (UTHR) on January 10, 2025, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On January 10, 2025, Christopher Patusky, a director of United Therapeutics Corporation, exercised stock options for 5,000 shares at a price of $175.43 per share.
- Following the exercise, Patusky sold a total of 5,000 shares in multiple transactions at weighted average prices ranging from $358.6549 to $363.8628.
- These transactions were executed under a Rule 10b5-1 trading plan established on August 27, 2024.
- After these transactions, Patusky directly owns 900 shares of common stock and indirectly owns 1,100 shares through a trust.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports transactions executed under a pre-existing plan. There is no indication of positive or negative sentiment regarding the company's prospects.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions. The use of a 10b5-1 plan suggests the transactions were pre-planned and not based on current market information.
Key Dates
| Date | Description |
|---|---|
| 06/26/2016 | Original date of the stock option grant. |
| 08/27/2024 | Date the Rule 10b5-1 trading plan was entered into. |
| 01/10/2025 | Date of stock option exercise and share sales. |
| 06/26/2025 | Expiration date of the stock options. |
| 01/13/2025 | Date of Form 4 signature. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.